DOCSLIB.ORG

Manufacturers with Signed Rebate Agreements, 07/01/2009

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Manufacturers with Signed Rebate Agreements, 07/01/2009 Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements July 1, 2009 NEW LABELER NAME START END SC NEW LABELER NAME START END SC 00002 ELI LILLY AND COMPANY 1/1/1991 Y 00126 COLGATE ORAL PHARMACEUTICAL 1/1/1991 Y 00003 E R SQUIBB AND SONS INC. 1/1/1991 Y 00131 SCHWARZ PHARMA, INC. 1/1/1991 Y 00004 HOFFMANN LAROCHE INC 1/1/1991 Y 00132 C B FLEET COMPANY INC. 1/1/1991 00005 LEDERLE LABORATORIES 1/1/1991 Y 00135 SMITHKLINE BEECHAM 1/1/1995 Y 00006 MERCK SHARP & DOHME 1/1/1991 Y D 00143 WEST-WARD PHARMACEUTICAL C 1/1/1991 9/30/2009 Y 00007 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00145 STIEFEL LABORATORIES INC. 1/1/1991 Y 00008 WYETH AYERST LABORATORIES 1/1/1991 Y 00149 PROCTER & GAMBLE PHARMACEU 1/1/1991 Y 00009 PHARMACIA AND UPJOHN 1/1/1991 Y 00165 BLAINE COMPANY, INC. 1/1/1992 00013 PHARMACIA AND UPJOHN 1/1/1991 Y 00168 E FOUGERA AND CO, DIV OF ALTAN 1/1/1991 Y 00015 INVAMED, INC 1/1/1991 Y 00169 NOVO NORDISK PHARMACEUTICAL 1/1/1991 Y 00023 ALLERGAN INC. 1/1/1991 Y 00172 ZENITH LABORATORIES, INC 1/1/1991 Y 00024 SANOFI SYNTHELABO 1/1/1991 00173 GLAXOSMITHKLINE 1/1/1991 Y 00025 PHARMACIA CORPORATION 1/1/1991 Y 00178 MISSION PHARMACAL COMPANY 1/1/1991 Y 00026 BAYER CORP PHARMACEUTICAL DI 1/1/1991 Y 00182 GOLDLINE LABORATORIES INC 1/1/1991 Y 00028 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00185 EON LABS MANUFACTURING, INC. 1/1/1991 Y 00029 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00186 ASTRAZENECA LP 1/1/1991 Y 00031 LEDERLE PIPERACILLIN 1/1/1991 Y 00187 ICN PHARMACEUTICALS INC. 1/1/1991 Y 00032 INTERNATIONAL LABORATORIES 1/1/1991 Y 00206 ELKINS-SINN 1/1/1991 Y 00037 CARTER- WALLACE, INC. 1/1/1991 Y 00212 SANDOZ NUTRITION 1/1/1991 00039 HOECHST MARION ROUSSEL INC. 1/1/1991 00224 KONSYL PHARMACEUTICALS, INC. 1/1/1992 00045 MCNEIL PHARMACEUTICAL 1/1/1991 Y 00225 B F ASHER COMPANY INC., 1/1/1991 00046 LEDERLE PARENTERALS 1/1/1991 Y 00228 PUREPAC PHARM. CO, DIV KALIPHA 1/1/1991 Y 00049 PFIZER-ROERIG 1/1/1991 Y 00245 UPSHER-SMITH LABORATORIES IN 1/1/1991 Y 00051 UNIMED PHARMACEUTICALS, INC 10/1/1997 Y 00256 FLEMING AND COMPANY 10/1/1991 Y 00052 ORGANON INC. 1/1/1991 00258 INWOOD LABORATORIES INC 1/1/1991 Y 00053 AVENTIS BEHRING 1/1/1991 00259 MERZ PHARMACEUTICALS 1/1/1991 00054 ROXANE LABORATORIES, INC. 1/1/1991 Y 00264 B BRAUN MEDICAL, INC. 1/1/1991 00056 DU PONT PHARMACEUTICALS 1/1/1991 Y 00276 MISEMER PHARMACEUTICAL, INC. 10/1/2006 00062 ORTHO MCNEIL PHARMACEUTICAL 1/1/1991 Y 00277 LASER INC 1/1/1991 Y 00064 HEALTHPOINT LTD 7/1/1995 Y 00281 SAVAGE LABS, DIV OF ALTANA INC 1/1/1991 Y 00065 ALCON LABORATORIES, INC. 1/1/1991 Y 00288 FLUORITAB CORPORATION 10/1/1991 00066 DERMIK LABORATORIES 1/1/1991 00299 GALDERMA, L.T. 1/1/1991 00067 NOVARTIS CONSUMER HEALTH INC 1/1/1991 00300 TAP PHARMACEUTICALS INC 1/1/1991 Y 00068 HOECHST MARION ROUSSEL INC. 1/1/1991 00310 ASTRAZENECA LP 1/1/1991 Y 00069 PFIZER INC 1/1/1991 Y 00327 UNITED GUARDIAN, INC. 1/1/1991 Y 00071 WARNER-LAMBERT 1/1/1991 Y 00338 BAXTER HEALTHCARE CORPORATI 1/1/1991 Y 00072 APOTHECON INC 1/1/1991 00378 MYLAN PHARMACEUTICALS, INC. 1/1/1991 Y 00074 ABBOTT LABORATORIES 1/1/1991 Y 00406 MALLINCKRODT SPECIALTY CHEMI 7/1/1993 Y 00075 RHONE-POULENC RORER PHARMA 1/1/1991 00409 HOSPIRA, INC 1/1/2005 00078 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00414 SUPPOSITORIA LABORATORIES 4/1/1994 Y 00083 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00421 THE FIELDING PHARMACEUTICAL C 1/1/1991 Y 00085 SCHERING PLOUGH PHARMACEUTI 1/1/1991 00430 WARNER CHILCOTT LABORATORIE 1/1/1998 00087 BRISTOL-MYERS SQUIBB COMPANY 1/1/1991 Y 00456 FOREST PHARMACEUTICALS INC 1/1/1991 Y 00088 HOECHST MARION ROUSSEL, INC. 1/1/1991 00462 PHARMADERM 7/1/2003 00089 3M PHARMACEUTICALS 1/1/1991 Y 00469 LYPHOMED DIVISION FUJISAWA US 1/1/1991 Y 00091 KREMERS URBAN CO. 1/1/1991 Y 00472 ALPHARMA, USPD 1/1/1991 Y 00093 TEVA PHARMACEUTICALS 1/1/1991 Y 00482 BRADLEY PHARMACEUTICALS, INC. 1/1/1991 Y 00095 ECR PHARMACEUTICALS 7/1/1993 Y 00485 EDWARDS PHARMACEUTICALS, IN 1/1/1991 Y 00096 PERSON & COVEY INC. 4/1/1999 00486 BEACH PRODUCTS INC 1/1/1991 Y 00113 L. PERRIGO COMPANY 7/1/2003 00487 NEPHRON PHARMACEUTICALS CO 4/1/1992 Y 00115 GLOBAL PHARMACEUTICAL COMPA 1/1/1991 Y 00496 FERNDALE LABORATORIES INC. 1/1/1991 Y 00116 XTTRIUM LABORATORIES, INC 1/1/2002 Y 00517 AMERICAN REGENT LABS, INC. 7/1/1993 00121 PHARMACEUTICAL ASSOCIATES, IN 1/1/1991 Y 00525 PAN AMERICAN LABORATORIES IN 1/1/1991 Y Page 1 of 6 N = NEW; D = DELETED; X = COVERED (NO REBATE AGREEMENT); Y=SENIORCARE REBATE AGREEMENT ON FILE Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements July 1, 2009 NEW LABELER NAME START END SC NEW LABELER NAME START END SC 00527 LANNETT COMPANY INC. 7/1/1994 Y 11098 AKORN MANUFACTURING 1/1/1996 Y 00535 GILBERT LABORATORIES 7/1/2002 Y N 11383 WEEKS & LEO CO., INC. 2/23/2009 00536 WATSON PHARMA, INC 1/1/1991 Y 11399 GTX, INC 7/1/2005 Y 00548 INTERNATIONAL MEDICATION SYS 1/1/1991 Y 11523 SCHERING PLOUGH HEALTHCARE 4/1/2003 00555 BARR LABORATORIES INC 1/1/1991 Y 11528 CENTRIX PHARMACEUTICAL, INC 7/1/2006 Y 00573 WYETH AYERST LABORATORIES 1/1/1991 11530 GLAXOSMITHKLINE 4/1/2002 Y 00574 PADDOCK LABORATORIES, INC. 1/1/1991 Y 11701 COLOPLAST CORPORATION 10/1/1991 Y 00575 BAKER NORTON PHARMACEUTICA 1/1/1991 Y 11980 ALLERGAN INC 1/1/1991 Y 00590 DU PONT PHARMACEUTICALS 1/1/1991 Y 12496 RECKITT & COLMAN PHARMACEUTI 1/1/1994 00591 WATSON PHARMA, INC 7/1/2001 Y 12593 RED RIIVER PHARMA MANUFACTU 4/1/2006 00597 BOEHRINGER INGELHEIM PHARMA 1/1/1991 Y 12830 R.A. MCNEIL 1/1/1991 Y 00603 QUALITEST PRODUCTS, INC. 1/1/1991 Y 12939 MARLOP PHARMACEUTICALS, INC. 1/1/1991 00615 VANGUARD LABS, INC 1/1/1991 Y 12948 NITROMED INC 10/1/2005 00641 ESI LEDERLE, INC 1/1/1991 Y 13107 AUROBINDO PHARMA USA, INC 7/1/2005 Y 00642 EVERETT LABORATORIES 1/1/1991 Y 13279 ALLAN PHARMACEUTICALS, LLC 10/1/2005 00677 UNITED RESEARCH LABORATORIE 1/1/1991 Y 13310 A R SCIENTIFIC, INC 1/1/2006 Y 00682 MARNEL PHARMACEUTICALS INC 1/1/1991 13436 VENUS 1/1/2009 00703 GENSIA SICOR PHARMACEUTICALS 7/1/1992 Y 13453 GRACEWAY PHARMACEUTICALS, L 4/1/2007 Y 00713 G AND W LABORATORIES INC 1/1/1991 Y 13478 BARRIER THERAPEUTICS 1/1/2006 00777 DISTA PRODS CO DIV OF ELI LILLY 1/1/1991 Y 13533 TALECRIS BIOTHERAPEUTICS, INC 10/1/2005 00781 GENEVA PHARMACEUTICALS, INC., 1/1/1991 Y 13548 CORIA LABORATORIES, LTD 4/1/2006 00785 UAD LABORATORIES INC 1/1/1991 Y 13551 FSC LABORATORIES, INC 1/1/2006 00813 PHARMICS INC. 1/1/1991 13632 ROSEMONT PHARMACEUTICALS LT 7/1/2007 00832 USL PHARMA, INC 1/1/1991 Y 13668 TORRENT PHARM, INC. 10/1/2007 Y 00884 PEDINOL PHARMACAL INC 1/1/1991 Y 13811 TRIGEN LABORATORIES, INC. 4/1/2006 00904 MAJOR PHARMACEUTICALS 1/1/1991 Y N 13845 DBA THE CHAO CENTER 4/30/2009 X 00941 BAXTER 12/1/1992 13913 DEPOMED, INC 10/1/2005 00944 BAXTER BIOTECH 1/1/1991 13925 SETON PHARMACEUTICALS, LLC 11/18/2008 00955 SANOFI SYNTHELABO 1/1/1996 14168 STONEBRIDGE PHARMA , LLC 1/1/2007 Y 00998 ALCON -PUERTO RICO- INC. 1/1/1991 Y 14290 TRIAX PHARMACEUTICALSLLC 7/1/2007 08880 KENDALL HEALTHCARE PRODUCT 1/1/1991 14508 SUN PHARMACEUTICAL INDUSTRIE 7/1/2006 Y 08884 SHERWOOD MEDICAL 1/1/1991 D 14565 NEUROSCI, INC. 1/1/2009 9/30/2009 Y 10019 BAXTER HEALTHCARE CORPORATI 10/1/2001 Y D 14629 AURIGA PHARMACEUTICALS, LLC 4/1/2006 9/30/2009 10122 CORNERSTONE BIOPHARM, INC 7/1/2005 15054 TERCICA, INC 4/1/2006 10139 GENERALMEDIX, INC. 12/9/2008 15127 SELECT BRAND DISTRIBUTORS 10/1/2006 10144 ACORDA THERAPEUTICS, INC 10/1/2005 15210 OTN GENERICS, INC. 10/1/2006 10147 PATRIOT PHARMACEUTICALS, LLC 4/1/2005 Y 15330 GENPHARM, L.P. 4/1/2006 Y 10148 COTHERIX, INC 7/1/2005 15338 APACE KY, LLC 1/1/2009 1/20 10158 GLAXOSMITHKLINE 4/1/2002 Y 15370 CARWIN ASSOCIATES, INC. 10/1/2006 Y 10267 CONTRACT PHARMACAL CORP 1/1/1991 Y 15456 ESPRIT PHARMA, INC. 4/1/2006 Y 10337 DOAK DERMATOLOGICS DIV 7/1/2002 Y 15584 BRISTOL-MYERS SQUIBB & GILEAD 7/1/2006 Y 10370 ANCHEN PHARMACEUTICALSINC 7/1/2007 15686 MIDLAND HEALTHCARE, LLC 4/1/2006 10454 SOLSTICE NEUROSCIENCES, INC 1/1/2006 15821 FOCUS LABORATORIES, INC. 10/1/2006 10518 DABUR ONCOLOGY, PLC. 10/1/2007 16103 PHARBEST PHARMACEUTICALS, IN 10/1/2006 10542 HILLESTAD INTERNATIONAL, INC. 4/1/1994 Y 16252 COBALT LABORATORIES, INC 10/1/2006 Y 10572 AFFORDABLE PHARMACEUTICALS, 1/1/2005 Y 16477 LASER PHARMACEUTICALS, LLC 7/1/2006 Y 10631 RANBAXY LABORATORIES INCORP 10/1/2005 16571 PACK PHARMACEUTICALS, L.L.C. 4/1/2006 Y 10702 KVK TECH INC 1/1/2007 Y 16714 NORTHSTAR RX, LLC 4/1/2008 Y 10768 PERRIGO PHARMACEUTICALS CO 4/1/2005 16729 ACCORD HEALTHCARE INC.
Load more

Recommended publications
  • Transcept Pharmaceuticals, Inc
    Table of Contents SCHEDULE 14A (RULE 14A 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by x Definitive Proxy Statement Rule 14a-6(e)(2)) ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.14a-12 Transcept Pharmaceuticals, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Table of Contents NOTICE OF ANNUAL MEETING OF STOCKHOLDERS JUNE 23, 2011 To Our Stockholders: NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of Transcept Pharmaceuticals, Inc., a Delaware corporation, will be held on Thursday, June 23, 2011, at 8:30 a.m., local time, at our office located at 1003 West Cutting Blvd., Suite 110, Point Richmond, California 94804, for the following purposes: 1.
    [Show full text]
  • Manufacturers and Wholesalers Street
    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
    [Show full text]
  • CONCERT PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material under §240.14a-12 CONCERT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 1 Concert Pharmaceuticals, Inc.
    [Show full text]
  • The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry
    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry By: Maitri Punjabi Honors Thesis Economics Department The University of North Carolina at Chapel Hill March 2016 Approved: ______________________________ Dr. Jonathan Williams Punjabi 2 Abstract This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market value from the years 1987 to 2010 by using U.S. patent and claim data. Over the years, firms have started shifting focus from primary innovation to secondary innovation as new ideas and new compounds become more difficult to generate. In this study, we analyze the impact of this patent portfolio shift on the market capitalization of pharmaceutical firms. After using firm fixed effects and the instrumental variable approach, we find that there exists a strong positive relationship between secondary innovations and the market value of the firm– in fact, we find a stronger relationship than is observed between primary innovation and market value. When focusing on the different levels of innovation within the industry, we find that this relationship is stronger for less-innovative firms (those that have produced fewer patents) than it is for highly- innovative firms. We also find that this relationship is stronger for firms that spend less on research and development, complementing earlier findings that research productivity is declining over time. Punjabi 3 Acknowledgements I would primarily like to thank my adviser, Dr. Jonathan Williams, for his patience and constant support. Without his kind and helpful attitude, this project would have been a much more frustrating process. Through his knowledge of the industry, I have gained valuable insight and have learned a great deal about a unique and growing field.
    [Show full text]
  • Management Liability Focus Johnson & Johnson 1
    Insured Profile Report – Management Liability Focus Johnson_________________________________________________________________________ & Johnson Company Profile Credit Details Location 1 Johnson and Johnson Plz Overall Credit Risk High Risk New Brunswick, NJ www.jnj.com Number of Legal Derogatory 84 Company Type Public Items Liability Amount $322,285.00 Formerly Known As N/A Experian Intelliscore 2.57 SIC Code 2834 SIC Code Description Pharmaceutical Preparations Experian Intelliscore Percentile 2.00 % of companies score lower and have higher credit risk Established 1955 Experian Commercial IntelliscoreSM is an all-industry commercial model using business information to predict business risk. Its Sales (in millions) $65,030.00 predictiveness is among the best on the market today The objective of the Commercial Intelliscore Model is to predict seriously Employees 117,900 derogatory payment behavior. Possible score range from 0 to 100, where 0 is high risk and 100 is low risk Total OSHA Violations 18 -Liability Amount is the total dollar amount of debtor’s legal liability, OSHA is an arm of the Department of Labor that conducts inspections of company including accounts in collection, tax liens,judgments and/or bankruptcies facilities with the goal of preventing work-related injuries, illnesses and deaths. -The Number of Legal Derogatory items are the sum of Tax-Lien Worksites that do not meet health and/or safety standards at the time of inspection may Count, Bankruptcy,Judgment, Collection-Counter and UCC Derog receive an OSHA violation. Total FDA NDC Drugs 177 The total number of FDA Drugs filed in the FDA NDC Drug Database. Business Description Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field.
    [Show full text]
  • Beyond Borders Global Biotechnology Report 2010
    Beyond borders Global biotechnology report 2010 To our clients and friends As economies around the world begin to recover from the worst diminished means, key constituents in the biotechnology economic crisis since the Great Depression, it is clear that a “new ecosystem — investors, pharmaceutical companies, payors, normal” is emerging. Among other things, this is a world in which governments and biotech firms — need to do more with less. capital flows are far more constrained than during the easy money- Companies that are able to develop creative solutions to boost fueled decade that preceded the downturn. What impact has this efficiency will be best positioned to succeed in the new normal. capital-constrained environment had on biotechnology — a business Readers of Beyond borders will notice some structural changes that is based on an enormous hunger for capital coupled with an in this year’s report. In prior years, we organized the report by exceptionally long path to commercial payback? geography, with sections on the Americas, Europe and Asia-Pacific. We set out to answer that question in this year’s Beyond borders. This year, we have instead organized the report thematically. As usual, we analyze key indicators of the industry’s performance: The Global perspective section brings together our point of view financing activity, deal trends, financial results, pipeline strength on salient trends and implications as well as some perspectives and product approvals. While the overall results are robust, the gap from company leaders. This is followed by a Country profiles between the industry’s haves and its have-nots has widened.
    [Show full text]
  • Pharmaceutical Company Contact Information (PDF)
    Pharmaceutical Company Contact Information - Rebate Filing - as of June 2018 Labeler Name Invoice Contact Phone Extension 00002 LILLY USA, LLC LISA NORTON (317) 276-2000 00003 ER SQUIBB AND SONS INC. LYNN LEWIS (609) 897-4731 00004 GENENTECH CONTRACT ADMINISTRATION (650) 866-2666 00005 LEDERLE LABORATORIES DAN MAGUIRE (484) 563-5097 00006 MERCK & CO., INC. DOUG BICKFORD (215) 652-0671 00007 SMITHKLINE BEECHAM DAVID BUCKLEY (215) 751-5690 00008 WYETH LABORATORIES JENNIFER WOOTEN (901) 215-1883 00009 PHARMACIA AND UPJOHN COMPANY/PFIZER JENNIFER WOOTEN (901) 215-1883 00013 PHARMACIA AND UPJOHN COMPANY NICHOLAS CHRISTODOULOU (336) 291-1053 00014 G. D. SEARLE & CO. CINDY MCDONALD (847) 581-5726 00015 MEAD JOHNSON AND COMPANY LYNN LEWIS (609) 897-4731 00016 PHARMACIA INC. BARBARA WINGET (908) 901-7254 00023 ALLERGAN INC SHOBHANA MINAWALA (714) 246-6205 00024 SANOFI WINTHROP PHARMACEUTICALS LAURIE DUNLAP, ADMIN., GOVT. OPERATIONS (212) 551-4198 00025 PHARMACIA CORPORATION NICHOLAS CHRISTODOULOU (336) 291-1053 00026 BAYER CORPORATION PHARMACEUTICAL DIV. LINDA WOLCHESKI (203) 812-6372 00028 NOVARTIS PHARMACEUTICALS (862) 778-8094 00029 SMITHKLINE BEECHAM DAVID BUCKLEY (215) 751-5690 00031 A. H. ROBINS COMPANY DAN MAGUIRE (610) 902-3222 00032 SOLVAY PHARMACEUTICALS STACEY LENOX (847) 937-3979 00033 SYNTEX LABORATORIES, INC. JANICE BRENNAN (973) 562-3494 00034 THE PURDUE FREDERICK COMPANY JUNE STOWE (203) 899-8035 00037 CARTER-WALLACE, INC. JAY R BRENNAN (609) 655-6163 00038 ASTRAZENECA LP DAVID WRIGHT (302) 886-2268 7820 00039 AVENTIS PHARMACEUTICALS (908) 981-7461 00043 NOVARTIS CONSUMER HEALTH, INC. EDWARD D. COLLINS (973) 781-6191 00044 KNOLL LABORATORIES DEBRA DEYOUNG (847) 937-4372 00045 MCNEIL PHARMACEUTICAL (908) 218-6777 00046 AYERST LABORATORIES (901) 215-1473 00047 WARNER CHILCOTT LABORATORIES LISA KAROLCHYK (973) 442-3262 00048 KNOLL PHARMACEUTICAL COMPANY DEBRA DEYOUNG (847) 937-4372 00049 ROERIG NICHOLAS CHRISTODOULOU (336) 291-1053 00051 UNIMED PHARMACEUTICALS, INC STACY LENOX (847) 937-3979 00052 ORGANON, USA, INC.
    [Show full text]
  • To Rapidly Navigate Through This Document RIGEL
    QuickLinks -- Click here to rapidly navigate through this document SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § 240.14a-12 RIGEL PHARMACEUTICALS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box) ý No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. 1. Title of each class of securities to which transaction applies: 2. Aggregate number of securities to which transaction applies: 3. Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined): 4. Proposed maximum aggregate value of transaction: 5. Total fee paid: o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. 6.
    [Show full text]
  • Allergan 2004 Annual Report
    ALLERGAN 2004 ANNUAL REPORT UNIFOCUSED UELY COMPANY PROFILE Allergan, Inc., with headquarters in Irvine, California, is a global specialty pharmaceutical company that develops and commercializes innovative products for the ophthalmology, neuromodulator, dermatology and other specialty markets. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities in over 100 countries that deliver value to our customers, satisfy unmet medical needs and improve patients’ lives. Driven by technology and innovation, Allergan addresses the needs of patients around the world with approximately 5,000 employees, a global research and development infrastructure and three state-of-the-art manufacturing plants. OUR VISION/OUR MISSION To continue as an innovative, technology driven, global health care company focused on pharmaceuticals in specialty markets that deliver value to customers, satisfy unmet medical needs and improve patients’ lives. To become the partner of choice for ever better health care through the value of our technological innovation, industry leadership, partnering skills and relationships, worldwide infrastructure, research and manufacturing capabilities. To develop a level of understanding of our customers in order to implement operational strategies that provide the greatest value for our customers and stockholders. FINANCIAL OVERVIEW Year Ended December 31, In millions, except per share data 2004 2003 2002 2001 2000 STATEMENT OF OPERATIONS HIGHLIGHTS (As reported under U.S. GAAP)
    [Show full text]
  • 2015 Valeant Pharmaceuticals Annual Report
    Be decisive, stay balanced, and always find ways to grow. A SIMPLE PHILOSOPHY 2014 ANNUAL REPORT company overview Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed in more than 100 countries. In our Developed Markets segment, we focus most of our efforts in the eye health, dermatology and neurology therapeutic classes. In the Emerging Market segment, we focus primarily on branded generics, OTC products and medical devices. We are diverse not only in our sources of revenue from our drug and medical devices portfolio, but also among the therapeutic classes and areas we serve. Valeant’s strategy is to focus our business on core geographies and therapeutic classes that offer attractive growth opportunities while maintaining our lower selling, general and administrative cost model and decentralized operating structure. We have an established portfolio of durable products with a focus on eye health and dermatology. Another critical element of our strategy is business development. We have completed numerous transactions over the past few years to expand our portfolio offering and geographic footprint including, among others, the acquisition of Bausch + Lomb. We will continue to pursue value-added business development opportunities as they arise. The growth of our business is further augmented through our lower risk, output-focused research and development model, which allows us to advance promising developmental programs to drive future commercial growth.
    [Show full text]
  • Table of Contents
    Table of contents Executive Summary Chapter 1 – Introduction Chapter 2 – Trends in drug delivery dealmaking 2.1. Introduction 2.2. Drug delivery partnering over the years 2.3. Bigpharma drug delivery dealmaking activity 2.4. Big biotech drug delivery dealmaking activity 2.5. Most active drug delivery dealmakers 2.6 Drug delivery partnering by deal type 2.7. Drug delivery partnering by disease type 2.8. Partnering by drug delivery technology type 2.9. Average deal terms for drug delivery partnering 2.9.1 Drug delivery headline values 2.9.2 Drug delivery upfront payments 2.9.3 Drug delivery milestone payments 2.9.4 Drug delivery royalty rates 2.10. The anatomy of drug delivery partnering 2.11. Drug delivery or specialty pharma? 2.11.1. Is specialty pharma the only way for drug delivery? 2.11.2. Best practice for optimizing drug delivery program development 2.11.3. The anatomy of a drug delivery deal 2.11.3.a. Case study 1: Alpharma – Durect 2.11.3.b. Case study 2: Bayer – MDRNA 2.11.3.c. Case study 3: Endo Pharmaceuticals – BioDelivery Sciences Chapter 3 – Leading drug delivery deals 3.1. Introduction 3.2. Top drug delivery deals by value Chapter 4 – Bigpharma drug delivery deals 4.1. Introduction 4.2. How to use bigpharma drug delivery partnering deals 4.3. Big pharma drug delivery partnering company profiles Abbott Actavis Inc (formerly Watson Pharmaceuticals) Actavis (merged with Watson Pharmaceuticals Oct 2012) Actelion Allergan Amgen Astellas AstraZeneca Baxter International Bayer Biogen Idec Boehringer Ingelheim Bristol-Myers Squibb Celgene CSL Daiichi Sankyo Dainippon Sumitomo Eisai Eli Lilly Endo Pharmaceuticals Forest Laboratories Galderma Gilead Sciences GlaxoSmithKline Grifols Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Menarini Merck & Co Merck KGaA Mylan Novartis Novo Nordisk Otsuka Pfizer Purdue Roche Sanofi Shionogi Shire Takeda Teva UCB Valeant Warner Chilcott Chapter 5 – Bigbiotech drug delivery deals 5.1.
    [Show full text]
  • CV Therapeutics 2005 Annual Report
    CV Therapeutics 2005 Annual Report Founded in 1990 by Louis Lange, M.D., Ph.D., CV Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new small molecule therapies for patients suffering from cardiovascular disease — the number one cause of death in the United States. We are dedicated to helping patients with unmet medical needs by bringing new drugs to market. THE VISION OF ONE COMPANY January 27, 2006 The FDA approval of RanexaTM represents the first new pharmaceutical approach to treat chronic angina in more than 20 years in the United States Despite the development of significant new therapies, cardiovascular disease ranks as the number one killer in the United States and today there are over 70 million people in the United States with cardiovascular disease, according to the American Heart Association. Our goal is to address unmet medical needs by developing innovative products, such as Ranexa, to treat patients. THE DEDICATION OF HUNDREDS THE HOPE OF MILLIONS Bringing new drugs to market requires years of support and commitment from many people, including physicians and scientists who serve as investigators or advisors for our programs. Together, their dedication is vital to our goal of improving the quality of treatment for cardiovascular diseases. This pioneering spirit is the foundation for scientific progress, and their contributions are critical for developing potential new drugs that could make an important difference in patients’ lives. CVT / 02 CVT / 03 Ranexa The FDA approval of RanexaTM (ranolazine extended-release tablets) in January 2006 represents the first new pharmaceutical approach to treat chronic angina in the United States in more than 20 years.
    [Show full text]